Real-world efficacy of treatment with benralizumab, dupilumab, mepolizumab and reslizumab for severe asthma: A systematic review and meta-analysis.

"CONFLICT OF INTEREST The authors know of no conflict of interest."

"Funding information"

"The study protocol was registered on the International Prospective Register of Systematic Reviews (PROSPERO, CRD42020207080). Grading of Recommendations, Assessment, Development and Evaluations (GRADE) and Preferred Reporting Items for Systematic Reviews and Meta‐Analyses guidelines were followed., The review aimed to assess adults and children with a diagnosis of asthma from 6 years of age treated with any nearly licenced or licenced biological therapies. Clinical outcomes examined included exacerbation rate, asthma control and reduction in the mean daily dose of OCS. Additional outcomes examined included forced expiratory volume in one second (FEV1), fractional exhaled nitric oxide (FeNO) and eosinophil count. Benralizumab, mepolizumab, reslizumab and dupilumab were examined. Omalizumab was excluded from this analysis as it has been in routine use for over a decade, and the authors chose to focus on newer agents where healthcare professionals have less clinical experience."